Clinical trials: Transthyretin Amyloidosis, open to volunteers
ATTR-CM
Quantitative-imaging in Cardiac Transthyretin Amyloidosis
Transthyretin amyloid cardiomyopathy (ATTR-CM), is a heart muscle disease that's stops the heart muscle working properly. With an ageing population, it is increasingly common but untreated, it has a poor prognosis.
- Trial name
- I-CARE (NCT05776212)
- Testing
- 18F-fluoride PET
- Where
- Netherlands
- Volunteers
- 140 people
- Sponsor
- University of Edinburgh
Amyloid Cardiomyopathy
Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy
This study aims to evaluate the safety and effectiveness of Enavogliflozin 0.3 mg, an SGLT2 inhibitor, in patients with amyloid cardiomyopathy.
- Trial name
- EMPACT (NCT07240844)
- Testing
- Enavogliflozin 0.3mg
- Where
- 2 sites in South Korea
- Volunteers
- 68 people
- Sponsor
- Seoul St. Mary's Hospital
Amyloidogenic Transthyretin (ATTR) Amyloidosis, Cardiac Amyloidosis
PET Imaging Study Using Evuzamitide to Detect Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans and Elevated TAD1 Levels
The goal of this study is to learn whether PET-CT imaging using evuzamitide can help diagnose transthyretin cardiac amyloidosis (ATTR-CA) in patients whose standard nuclear imaging results are unclear but who have elevated TAD1…
- Trial name
- TRACE (NCT07538518)
- Testing
- Evuzamitide
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Lorena Saelices
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Study of Acoramidis in Patients With Transthyretin Amyloid Cardiomyopathy
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive heart disease caused by the buildup of an abnormal protein, called transthyretin (TTR), in the heart.
- Trial name
- MOSAIC-TTR (NCT07791160)
- Testing
- Acoramidis
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Bayer
Cardiac Amyloidosis
PET Imaging With [18F]Fluselenamyl in People With Cardiac Amyloidosis
This observational study will evaluate the imaging performance of the investigational positron emission tomography (PET) radiotracer[18F]Fluselenamyl (FSA) in individuals with cardiac amyloidosis.
- Trial name
- FSA-CA (NCT07771621)
- Testing
- [18F]Fluselenamyl (FSA)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Washington University School of Medicine
ATTR Amyloidosis Wild Type, ATTR Gene Mutation
ATTR Cardiac Amyloidosis in a Selected Population
Patients operated for carpal tunnel syndrome (CTS) at Ålesund Hospital (200 patients) will have a biopsy to diagnose ATTR amyloidosis. Patients with positive biopsy will be examined to decide wether they have cardiac amyloidosis.
- Conditions
- ATTR Amyloidosis Wild Type, ATTR Gene Mutation, Carpal Tunnel Syndrome, Cardiac Amyloidosis
- Trial name
- NCT06458374
- Where
- Norway
- Volunteers
- 180 people
- Sponsor
- Helse Møre og Romsdal HF
Light Chain Cardiac Amyloidosis
CAR-NK Therapy for Cardiac Amyloidosis
Relapsed/refractory (R/R) light chain cardiac amyloidosis is associated with a poor prognosis, and cellular immunotherapy constitutes a crucial therapeutic modality for these patients.
- Trial name
- NCT07504289
- Testing
- CAR-NK
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Transthyretin (TTR) Amyloid Cardiomyopathy, Cardiac Amyloidosis
Liver and Coagulation Disorders in Cardiac Transthyretin Amyloidosis
Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive infiltrative cardiomyopathy caused by the deposition of misfolded transthyretin protein within the myocardium.
- Conditions
- Transthyretin (TTR) Amyloid Cardiomyopathy, Cardiac Amyloidosis, Cardiomyopathies, Wild-Type Transthyretin Cardiac Amyloidosis
- Trial name
- LICA2025 (NCT07766135)
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- University of Messina
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from…
- Trial name
- NCT06679946
- Testing
- Vutrisiran
- Where
- 87 sites in United States, Argentina and 15 more
- Volunteers
- 700 people
- Sponsor
- Alnylam Pharmaceuticals
Hereditary Transthyretin Amyloidosis
An Interventional Pilot Study to Investigate the Feasibility and Acceptance of a Structured Psychological Support Program for Patients, Caregivers, and Presymptomatic Carriers in Hereditary Transthyretin Amyloidosis With Cardiomyopathy
Hereditary transthyretin amyloidosis (ATTRv) is a genetic, progressive and disabling disease that affects multiple organs and severely compromises the quality of life of patients and their families.
- Trial name
- AMH (NCT06907186)
- Testing
- Psychological Support
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Amyloid Cardiomyopathy, Transthyretin Cardiac Amyloidosis
Exercise Training in Transthyretin Cardiac Amyloidosis
Transthyretin cardiac amyloidosis causes debilitating heart failure in older adults. The proposed research will develop a personalized exercise training program to improve functional capacity in patients on optimal treatment for…
- Trial name
- NCT05797857
- Testing
- Exercise Training
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Brigham and Women's Hospital
Transthyretin Amyloidosis, Heart Failure
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF)…
- Conditions
- Transthyretin Amyloidosis, Heart Failure, Heart Failure, Diastolic, Amyloidosis
- Trial name
- TTRinHFpEF (NCT05577819)
- Testing
- 99mTc-pyrophosphate Scintigraphy
- Where
- United States
- Volunteers
- 515 people
- Sponsor
- Massachusetts General Hospital
Amyloid Cardiomyopathy
Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)
Cardiac transthyretin amyloidosis (ATTR), caused by ventricular depositions of misfolded transthyretin, results in an infiltrative cardiomyopathy, progressing from pronounced myocardial wall thickening, diastolic and systolic…
- Trial name
- B-CARE (NCT04776824)
- Where
- 7 sites in Switzerland
- Volunteers
- 300 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Cardiac Amyloidosis, Left Ventricular Hypertrophy
Detection of Cardiac Amyloidosis Using Right Ventricular Sensing Amplitude in Patients With Left Ventricular Hypertrophy
This multicenter prospective study aims to evaluate the diagnostic performance of right ventricular sensing amplitude measured during cardiac implantable electronic device (CIED) implantation (pacemaker or defibrillator) to…
- Conditions
- Cardiac Amyloidosis, Left Ventricular Hypertrophy, Conduction Abnormality
- Trial name
- DETECT-AMY (NCT07734285)
- Testing
- Cardiac amyloidosis screening during CIED implantation
- Volunteers
- 242 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Transthyroxin Amyloidosis Cardiomyopathy
Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy
This study is a single-arm, open-label, single-dose escalation trial aimed at evaluating the safety and tolerability of YOLT-201 treatment in patients with Transthyretin Amyloidosis Cardiomyopathy （ATTR-CM）, as well as assessing…
- Trial name
- NCT06082050
- Testing
- YOLT-201
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Zhejiang University
ATTR Amyloidosis With Cardiomyopathy, Heart Failure
Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
The TRACE-AI Diagnostic Study will evaluate the performance of artificial intelligence (AI) models applied to electrocardiograms (AI-ECG) and echocardiograms (AI-Echo) to identify transthyretin amyloid cardiomyopathy (ATTR-CM) in…
- Trial name
- TRACE-AI Yale (NCT07398950)
- Testing
- ATTR-CM AI-ECG and AI-Echo Model
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Yale University
AL Amyloidosis (AL), Cardiac Amyloidosis
Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis
1. Goal of the Study: The goal of this prospective observational study is to develop and validate a novel, non-invasive method for predicting the prognosis of patients with light-chain cardiac amyloidosis (AL-CA).
- Trial name
- AL-CA (NCT07103863)
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Beijing Anzhen Hospital
Bilateral Carpal Tunnel Syndrome (Diagnosis), Cardiac Amyloidosis
Early Screening for Cardiac Amyloid Using a History of Bilateral Carpal Tunnel Syndrome
Cardiac amyloidosis is a condition where abnormal protein deposits build up in the heart, making it stiff and causing it to work less effectively.
- Trial name
- NCT07580872
- Testing
- Technetium-99m Pyrophosphate (Tc-99m PYP) Scan
- Volunteers
- 139 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Carpal Tunnel, Transthyretin Amyloidosis
Concordance for Transthyretin Amyloidosis Between Synovial Biopsy and Anterior Carpal Ligament Biopsy
Transthyretin amyloidosis (ATTR) is an underdiagnosed condition that can present early as carpal tunnel syndrome, sometimes preceding cardiac involvement by several years.
- Trial name
- ATTR2026 (NCT07644325)
- Testing
- Annular ligament biopsy
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Clinique Saint Jean, France
Amyloid, Cardiac Amyloidosis
[18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis
[18F]FT8, a derivative of 1-(4-pyridyl)-4-piperazinyl arene ([18F]TPZA), exhibits high affinity for AL amyloid in myocardial tissue sections and shows no significant binding to transthyretin amyloid.
- Conditions
- Amyloid, Cardiac Amyloidosis, Amyloidosis, Healthy Subjects
- Trial name
- NCT07232459
- Testing
- [18F]FT8
- Where
- 3 sites in China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University